Efficacy of atypical antipsychotics in depressive syndroms;La place des antipsychotiques atypiques dans le traitement des syndromes dépressifs

Encephale

Volumn 30, Issue 6, 2004, Pages 583-589

  Quintin, Ph ^a,b   Thomas, P ^c  

^a Lilly France   (France)

^b HÔPITAL LOUIS MOURIER   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Antidepressants; Atypical antipsychotics; Bipolar disorders; Depressive symptoms; Major depression; Psychotic depression; SSRI

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR; FLUOXETINE; FLUVOXAMINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; OLANZAPINE; PAROXETINE; PERPHENAZINE; RISPERIDONE; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGITATION; AKATHISIA; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSION; DEPRESSIVE PSYCHOSIS; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DYSTHYMIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INSOMNIA; MAJOR DEPRESSION; MANIA; MONOAMINERGIC SYSTEM; NEGATIVE SYNDROME; PREFRONTAL CORTEX; SEROTONIN RELEASE; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOM; SYNAPSE; TARDIVE DYSKINESIA;

EID: 12444290822     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0013-7006(04)95474-7     Document Type: Article

References (51)

1. ADLI M, ROSSIUS W, BAUER M. Olanzapine in the treatment of depressive disorders with psychotic symptoms. Nervenarzt 1999; 70: 68-71.
2. 2C and alpha 2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol 1997; 20: 210-4.
3. ALTSHULER LL, POST RM, LEVERICH GS et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995; 152: 1130-8.
4. AMERICAN PSYCHIATRIC ASSOCIATION. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington DC: American Psychiatric Association. 1994.
5. AMERICAN PSYCHIATRIC ASSOCIATION. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159 (Suppl 4): 1-50.
6. AMORE M, JORI MC, AMISERT INVESTIGATORS. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2001; 16: 317-24.
7. BOYER P, LECRUBIER Y, STALLA-BOURDILLON A et al. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology 1999; 39: 25-32.
8. CALABRESE JR, BOWDEN CL, SACHS GS et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 79-88.
9. CALABRESE JR, SULLIVAN JR, BOWDEN CL et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002; 63: 1012-9.
10. CASEY DE. Affective disorders and tardive dyskinesia. Encephale 1988; 14: 221-6.
11. CASSANO GB, JORI MC, AMIMAJOR GROUP. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2002; 17: 27-32.
12. CHAN CH, JANICAK PG, DAVIS JM et al. Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants. J Clin Psychiatry 1987; 48: 197-200.
13. CORRELL CU, LEUCHT S, KANE JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414-25
14. CORYA SA, ANDERSEN SW, DETKE HC et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxétine combination: a 76-week open-label study. J Clin Psychiatry 2003; 64: 1349-56.
15. CULPEPPER L. Evidence for using atypical antipsychotics in mood and anxiety disorders. Prim Care Companion J Clin Psychiatry 2003; 5 (Suppl 3): 27-32.
16. DASSA D, KALADJIAN A, AZORIN JM et al. Clozapine in the treatment of psychotic refractory depression. Br J Psychiatry 1993; 163: 822-4.
17. FAWCETT J, MARCUS RN, ANTON SF et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995; 56 (Suppl 6): 37-42.
18. HILLERT A, MAIER W, WETZEL H et al. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome - a functional approach. Pharmacopsychiatry 1992; 25: 213-7.
19. HILTY DM, BRADY KT, HALES RE. A review of bipolar disorder among adults. Psychiatr Serv 1999; 50: 201-13.
20. HIROSE S, ASHBY CR Jr. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry 2002; 63: 733-6.
21. JUDD LL, AKISKAL HS, SCHETTLER PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-7.
22. LECRUBIER Y, BOYER P, TURJANSKI S et al. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J Affect Disord 1997; 43: 95-103.
23. MATTHEWS JD, BOTTONARI KA, POLANIA LM et al. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J Clin Psychiatry 2002; 63: 1164-70.
24. MELTZER HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999; (Suppl 2): 106S-15S.
25. NELSON EB, RIELAGE E, WELGE JA et al. An open trial of olanzapine in the treatment of patients with psychotic depression. Ann Clin Psychiatry 2001; 13: 147-51.
26. OSTROFF RB, NELSON JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999; 60: 256-9.
27. PANI L, GESSA GL. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Mol Psychiatry 2002; 7: 247-53.
28. RANJAN R, MELTZER HY. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 1996; 40: 253-8.
29. RAVIZZA L. Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators. J Psychopharmacol 1999; 13: 248-54.
30. ROBERTSON MM, TRIMBLE MR. Major tranquillisers used as antidepressants. A review. J Affect Disord 1982; 4: 173-93.
31. ROTHSCHILD AJ, BATES KS, BOEHRINGER KL et al. Olanzapine response in psychotic depression. J Clin Psychiatry 1999; 60: 116-8.
32. ROTHSCHILD AJ, DUVAL SE. How long should patients with psychotic depression stay on the antipsychotic medication? J Clin Psychiatry 2003; 64: 390-6.
33. ROTHSCHILD AJ, SAMSON JA, BESSETTE MP et al. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 1993; 54: 338-42.
34. RUSH AJ, ARMITAGE R, GILLIN JC et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry 1998; 44: 3-14.
35. SCHATZBERG AF, ROTHSCHILD AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM IV? Am J Psychiatry 1992; 149: 733-45.
36. SCHMITT A, BRAUS DF. Effective treatment of depressive disorder with psychotic symptoms by olanzapine combination therapy. Dtsch Med Wochenschr 2000; 125: 1526-9.
37. SHELTON RC, TOLLEFSON GD, TOHEN M et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131-4.
38. SIMPSON GM, EI SHESHAI A, RADY A et al. Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression. J Clin Psychiatry 2003; 64: 959-65.
39. SMERALDI E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord 1998; 48: 47-56.
40. THASE ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999; 60 (Suppl 17): 28-31.
41. THASE ME. Treatment issues related to sleep and depression. J Clin Psychiatry 2000; 61 (Suppl 11): 46-50.
42. THASE ME. What role do atypical antipsychotic drugs have in treatment resistant depression? J Clin Psychiatry 2002; 63: 95-103.
43. TOHEN M, BAKER RW, ALTSHULER LL et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002; 159: 1011-7.
44. TOHEN M, JACOBS TG, GRUNDY SL et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000; 57: 841-9.
45. TOHEN M, SANGER TM, McELROY SL et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156: 702-9.
46. TOHEN M, VIETA E, CALABRESE J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-88.
47. TOLLEFSON GD, SANGER TM, LU Y et al. Depressive signs and symptoms in schizophrenia : a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55: 250-8.
48. VYTHILINGAM M, CHEN J, BREMNER JD et al. Psychotic depression and mortality. Am J Psychiatry 2003; 160: 574-6.
49. WOLFERSDORF M, BARG T, KONIG F et al. Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychiatry 1995; 28: 56-60.
50. WEHR TA, GOODWIN FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 1979; 36: 555-9.
51. ZHANG W, PERRY KW, WONG DT et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000; 23: 250-62.